世界の肺高血圧症治療薬市場予測2023-2029：IK-3001、クエン酸シルデナフィルIMD、IK-7002、リオシグアト、SAR-407899、その他

【英語タイトル】Pulmonary Hypertension Drug Market, Global Outlook and Forecast 2023-2029

・商品コード：MMG23LY8620
・発行会社（調査会社）：Market Monitor Global
・発行日：2023年7月
・ページ数：79
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の肺高血圧症治療薬市場規模と予測を収録しています。・世界の肺高血圧症治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の肺高血圧症治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の肺高血圧症治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「IK-3001」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

肺高血圧症治療薬のグローバル主要企業は、Sanofi、 Vectura Group plc、 Bayer AG、 Ikaria Inc.、 Proreo Pharma AG、 Vicore Pharma AB、 Biolab Sanus Farmaceutica Ltda.、 Hanmi Pharmaceuticals, Co. Ltd.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、肺高血圧症治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の肺高血圧症治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の肺高血圧症治療薬市場：タイプ別市場シェア、2022年
・IK-3001、クエン酸シルデナフィルIMD、IK-7002、リオシグアト、SAR-407899、その他

世界の肺高血圧症治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の肺高血圧症治療薬市場：用途別市場シェア、2022年
・診療所、病院、その他

世界の肺高血圧症治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の肺高血圧症治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における肺高血圧症治療薬のグローバル売上、2018年-2023年
・主要企業における肺高血圧症治療薬のグローバル売上シェア、2022年
・主要企業における肺高血圧症治療薬のグローバル販売量、2018年-2023年
・主要企業における肺高血圧症治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Sanofi、 Vectura Group plc、 Bayer AG、 Ikaria Inc.、 Proreo Pharma AG、 Vicore Pharma AB、 Biolab Sanus Farmaceutica Ltda.、 Hanmi Pharmaceuticals, Co. Ltd.

*************************************************************

・調査・分析レポートの概要
肺高血圧症治療薬市場の定義
市場セグメント
世界の肺高血圧症治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の肺高血圧症治療薬市場規模
世界の肺高血圧症治療薬市場規模：2022年 VS 2029年
世界の肺高血圧症治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの肺高血圧症治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の肺高血圧症治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：IK-3001、クエン酸シルデナフィルIMD、IK-7002、リオシグアト、SAR-407899、その他
肺高血圧症治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：診療所、病院、その他
肺高血圧症治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別肺高血圧症治療薬市場規模 2022年と2029年
地域別肺高血圧症治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Sanofi、 Vectura Group plc、 Bayer AG、 Ikaria Inc.、 Proreo Pharma AG、 Vicore Pharma AB、 Biolab Sanus Farmaceutica Ltda.、 Hanmi Pharmaceuticals, Co. Ltd.
...

This report aims to provide a comprehensive presentation of the global market for Pulmonary Hypertension Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Hypertension Drug. This report contains market size and forecasts of Pulmonary Hypertension Drug in global, including the following market information:
Global Pulmonary Hypertension Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Pulmonary Hypertension Drug Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Pulmonary Hypertension Drug companies in 2022 (%)
The global Pulmonary Hypertension Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
IK-3001 Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Pulmonary Hypertension Drug include Sanofi, Vectura Group plc, Bayer AG, Ikaria Inc., Proreo Pharma AG, Vicore Pharma AB, Biolab Sanus Farmaceutica Ltda. and Hanmi Pharmaceuticals, Co. Ltd., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Pulmonary Hypertension Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pulmonary Hypertension Drug Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Pulmonary Hypertension Drug Market Segment Percentages, by Type, 2022 (%)
IK-3001
Sildenafil Citrate IMD
IK-7002
Riociguat
SAR-407899
Others
Global Pulmonary Hypertension Drug Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Pulmonary Hypertension Drug Market Segment Percentages, by Application, 2022 (%)
Clinic
Hospital
Others
Global Pulmonary Hypertension Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Pulmonary Hypertension Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pulmonary Hypertension Drug revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Pulmonary Hypertension Drug revenues share in global market, 2022 (%)
Key companies Pulmonary Hypertension Drug sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Pulmonary Hypertension Drug sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Vectura Group plc
Bayer AG
Ikaria Inc.
Proreo Pharma AG
Vicore Pharma AB
Biolab Sanus Farmaceutica Ltda.
Hanmi Pharmaceuticals, Co. Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Pulmonary Hypertension Drug, market overview.
Chapter 2: Global Pulmonary Hypertension Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Pulmonary Hypertension Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pulmonary Hypertension Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Pulmonary Hypertension Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Pulmonary Hypertension Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Pulmonary Hypertension Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Pulmonary Hypertension Drug Overall Market Size
2.1 Global Pulmonary Hypertension Drug Market Size: 2022 VS 2029
2.2 Global Pulmonary Hypertension Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Pulmonary Hypertension Drug Sales: 2018-2029
3 Company Landscape
3.1 Top Pulmonary Hypertension Drug Players in Global Market
3.2 Top Global Pulmonary Hypertension Drug Companies Ranked by Revenue
3.3 Global Pulmonary Hypertension Drug Revenue by Companies
3.4 Global Pulmonary Hypertension Drug Sales by Companies
3.5 Global Pulmonary Hypertension Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Pulmonary Hypertension Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Pulmonary Hypertension Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Pulmonary Hypertension Drug Players in Global Market
3.8.1 List of Global Tier 1 Pulmonary Hypertension Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Pulmonary Hypertension Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Pulmonary Hypertension Drug Market Size Markets, 2022 & 2029
4.1.2 IK-3001
4.1.3 Sildenafil Citrate IMD
4.1.4 IK-7002
4.1.5 Riociguat
4.1.6 SAR-407899
4.1.7 Others
4.2 By Type – Global Pulmonary Hypertension Drug Revenue & Forecasts
4.2.1 By Type – Global Pulmonary Hypertension Drug Revenue, 2018-2023
4.2.2 By Type – Global Pulmonary Hypertension Drug Revenue, 2024-2029
4.2.3 By Type – Global Pulmonary Hypertension Drug Revenue Market Share, 2018-2029
4.3 By Type – Global Pulmonary Hypertension Drug Sales & Forecasts
4.3.1 By Type – Global Pulmonary Hypertension Drug Sales, 2018-2023
4.3.2 By Type – Global Pulmonary Hypertension Drug Sales, 2024-2029
4.3.3 By Type – Global Pulmonary Hypertension Drug Sales Market Share, 2018-2029
4.4 By Type – Global Pulmonary Hypertension Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Pulmonary Hypertension Drug Market Size, 2022 & 2029
5.1.2 Clinic
5.1.3 Hospital
5.1.4 Others
5.2 By Application – Global Pulmonary Hypertension Drug Revenue & Forecasts
5.2.1 By Application – Global Pulmonary Hypertension Drug Revenue, 2018-2023
5.2.2 By Application – Global Pulmonary Hypertension Drug Revenue, 2024-2029
5.2.3 By Application – Global Pulmonary Hypertension Drug Revenue Market Share, 2018-2029
5.3 By Application – Global Pulmonary Hypertension Drug Sales & Forecasts
5.3.1 By Application – Global Pulmonary Hypertension Drug Sales, 2018-2023
5.3.2 By Application – Global Pulmonary Hypertension Drug Sales, 2024-2029
5.3.3 By Application – Global Pulmonary Hypertension Drug Sales Market Share, 2018-2029
5.4 By Application – Global Pulmonary Hypertension Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Pulmonary Hypertension Drug Market Size, 2022 & 2029
6.2 By Region – Global Pulmonary Hypertension Drug Revenue & Forecasts
6.2.1 By Region – Global Pulmonary Hypertension Drug Revenue, 2018-2023
6.2.2 By Region – Global Pulmonary Hypertension Drug Revenue, 2024-2029
6.2.3 By Region – Global Pulmonary Hypertension Drug Revenue Market Share, 2018-2029
6.3 By Region – Global Pulmonary Hypertension Drug Sales & Forecasts
6.3.1 By Region – Global Pulmonary Hypertension Drug Sales, 2018-2023
6.3.2 By Region – Global Pulmonary Hypertension Drug Sales, 2024-2029
6.3.3 By Region – Global Pulmonary Hypertension Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Pulmonary Hypertension Drug Revenue, 2018-2029
6.4.2 By Country – North America Pulmonary Hypertension Drug Sales, 2018-2029
6.4.3 US Pulmonary Hypertension Drug Market Size, 2018-2029
6.4.4 Canada Pulmonary Hypertension Drug Market Size, 2018-2029
6.4.5 Mexico Pulmonary Hypertension Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Pulmonary Hypertension Drug Revenue, 2018-2029
6.5.2 By Country – Europe Pulmonary Hypertension Drug Sales, 2018-2029
6.5.3 Germany Pulmonary Hypertension Drug Market Size, 2018-2029
6.5.4 France Pulmonary Hypertension Drug Market Size, 2018-2029
6.5.5 U.K. Pulmonary Hypertension Drug Market Size, 2018-2029
6.5.6 Italy Pulmonary Hypertension Drug Market Size, 2018-2029
6.5.7 Russia Pulmonary Hypertension Drug Market Size, 2018-2029
6.5.8 Nordic Countries Pulmonary Hypertension Drug Market Size, 2018-2029
6.5.9 Benelux Pulmonary Hypertension Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Pulmonary Hypertension Drug Revenue, 2018-2029
6.6.2 By Region – Asia Pulmonary Hypertension Drug Sales, 2018-2029
6.6.3 China Pulmonary Hypertension Drug Market Size, 2018-2029
6.6.4 Japan Pulmonary Hypertension Drug Market Size, 2018-2029
6.6.5 South Korea Pulmonary Hypertension Drug Market Size, 2018-2029
6.6.6 Southeast Asia Pulmonary Hypertension Drug Market Size, 2018-2029
6.6.7 India Pulmonary Hypertension Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Pulmonary Hypertension Drug Revenue, 2018-2029
6.7.2 By Country – South America Pulmonary Hypertension Drug Sales, 2018-2029
6.7.3 Brazil Pulmonary Hypertension Drug Market Size, 2018-2029
6.7.4 Argentina Pulmonary Hypertension Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Pulmonary Hypertension Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Pulmonary Hypertension Drug Sales, 2018-2029
6.8.3 Turkey Pulmonary Hypertension Drug Market Size, 2018-2029
6.8.4 Israel Pulmonary Hypertension Drug Market Size, 2018-2029
6.8.5 Saudi Arabia Pulmonary Hypertension Drug Market Size, 2018-2029
6.8.6 UAE Pulmonary Hypertension Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Sanofi
7.1.1 Sanofi Company Summary
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Pulmonary Hypertension Drug Major Product Offerings
7.1.4 Sanofi Pulmonary Hypertension Drug Sales and Revenue in Global (2018-2023)
7.1.5 Sanofi Key News & Latest Developments
7.2 Vectura Group plc
7.2.1 Vectura Group plc Company Summary
7.2.2 Vectura Group plc Business Overview
7.2.3 Vectura Group plc Pulmonary Hypertension Drug Major Product Offerings
7.2.4 Vectura Group plc Pulmonary Hypertension Drug Sales and Revenue in Global (2018-2023)
7.2.5 Vectura Group plc Key News & Latest Developments
7.3 Bayer AG
7.3.1 Bayer AG Company Summary
7.3.2 Bayer AG Business Overview
7.3.3 Bayer AG Pulmonary Hypertension Drug Major Product Offerings
7.3.4 Bayer AG Pulmonary Hypertension Drug Sales and Revenue in Global (2018-2023)
7.3.5 Bayer AG Key News & Latest Developments
7.4 Ikaria Inc.
7.4.1 Ikaria Inc. Company Summary
7.4.2 Ikaria Inc. Business Overview
7.4.3 Ikaria Inc. Pulmonary Hypertension Drug Major Product Offerings
7.4.4 Ikaria Inc. Pulmonary Hypertension Drug Sales and Revenue in Global (2018-2023)
7.4.5 Ikaria Inc. Key News & Latest Developments
7.5 Proreo Pharma AG
7.5.1 Proreo Pharma AG Company Summary
7.5.2 Proreo Pharma AG Business Overview
7.5.3 Proreo Pharma AG Pulmonary Hypertension Drug Major Product Offerings
7.5.4 Proreo Pharma AG Pulmonary Hypertension Drug Sales and Revenue in Global (2018-2023)
7.5.5 Proreo Pharma AG Key News & Latest Developments
7.6 Vicore Pharma AB
7.6.1 Vicore Pharma AB Company Summary
7.6.2 Vicore Pharma AB Business Overview
7.6.3 Vicore Pharma AB Pulmonary Hypertension Drug Major Product Offerings
7.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Sales and Revenue in Global (2018-2023)
7.6.5 Vicore Pharma AB Key News & Latest Developments
7.7 Biolab Sanus Farmaceutica Ltda.
7.7.1 Biolab Sanus Farmaceutica Ltda. Company Summary
7.7.2 Biolab Sanus Farmaceutica Ltda. Business Overview
7.7.3 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Major Product Offerings
7.7.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales and Revenue in Global (2018-2023)
7.7.5 Biolab Sanus Farmaceutica Ltda. Key News & Latest Developments
7.8 Hanmi Pharmaceuticals, Co. Ltd.
7.8.1 Hanmi Pharmaceuticals, Co. Ltd. Company Summary
7.8.2 Hanmi Pharmaceuticals, Co. Ltd. Business Overview
7.8.3 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Major Product Offerings
7.8.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales and Revenue in Global (2018-2023)
7.8.5 Hanmi Pharmaceuticals, Co. Ltd. Key News & Latest Developments
8 Global Pulmonary Hypertension Drug Production Capacity, Analysis
8.1 Global Pulmonary Hypertension Drug Production Capacity, 2018-2029
8.2 Pulmonary Hypertension Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Pulmonary Hypertension Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Pulmonary Hypertension Drug Supply Chain Analysis
10.1 Pulmonary Hypertension Drug Industry Value Chain
10.2 Pulmonary Hypertension Drug Upstream Market
10.3 Pulmonary Hypertension Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Pulmonary Hypertension Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Pulmonary Hypertension Drug in Global Market
Table 2. Top Pulmonary Hypertension Drug Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Pulmonary Hypertension Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Pulmonary Hypertension Drug Revenue Share by Companies, 2018-2023
Table 5. Global Pulmonary Hypertension Drug Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Pulmonary Hypertension Drug Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Pulmonary Hypertension Drug Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Pulmonary Hypertension Drug Product Type
Table 9. List of Global Tier 1 Pulmonary Hypertension Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Pulmonary Hypertension Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Pulmonary Hypertension Drug Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Pulmonary Hypertension Drug Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Pulmonary Hypertension Drug Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Pulmonary Hypertension Drug Sales (K Pcs), 2018-2023
Table 15. By Type - Global Pulmonary Hypertension Drug Sales (K Pcs), 2024-2029
Table 16. By Application – Global Pulmonary Hypertension Drug Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Pulmonary Hypertension Drug Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Pulmonary Hypertension Drug Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Pulmonary Hypertension Drug Sales (K Pcs), 2018-2023
Table 20. By Application - Global Pulmonary Hypertension Drug Sales (K Pcs), 2024-2029
Table 21. By Region – Global Pulmonary Hypertension Drug Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Pulmonary Hypertension Drug Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Pulmonary Hypertension Drug Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Pulmonary Hypertension Drug Sales (K Pcs), 2018-2023
Table 25. By Region - Global Pulmonary Hypertension Drug Sales (K Pcs), 2024-2029
Table 26. By Country - North America Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Pulmonary Hypertension Drug Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Pulmonary Hypertension Drug Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Pulmonary Hypertension Drug Sales, (K Pcs), 2024-2029
Table 30. By Country - Europe Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Pulmonary Hypertension Drug Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Pulmonary Hypertension Drug Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Pulmonary Hypertension Drug Sales, (K Pcs), 2024-2029
Table 34. By Region - Asia Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Pulmonary Hypertension Drug Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Pulmonary Hypertension Drug Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Pulmonary Hypertension Drug Sales, (K Pcs), 2024-2029
Table 38. By Country - South America Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Pulmonary Hypertension Drug Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Pulmonary Hypertension Drug Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Pulmonary Hypertension Drug Sales, (K Pcs), 2024-2029
Table 42. By Country - Middle East & Africa Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Pulmonary Hypertension Drug Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Pulmonary Hypertension Drug Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Pulmonary Hypertension Drug Sales, (K Pcs), 2024-2029
Table 46. Sanofi Company Summary
Table 47. Sanofi Pulmonary Hypertension Drug Product Offerings
Table 48. Sanofi Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. Sanofi Key News & Latest Developments
Table 50. Vectura Group plc Company Summary
Table 51. Vectura Group plc Pulmonary Hypertension Drug Product Offerings
Table 52. Vectura Group plc Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. Vectura Group plc Key News & Latest Developments
Table 54. Bayer AG Company Summary
Table 55. Bayer AG Pulmonary Hypertension Drug Product Offerings
Table 56. Bayer AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. Bayer AG Key News & Latest Developments
Table 58. Ikaria Inc. Company Summary
Table 59. Ikaria Inc. Pulmonary Hypertension Drug Product Offerings
Table 60. Ikaria Inc. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. Ikaria Inc. Key News & Latest Developments
Table 62. Proreo Pharma AG Company Summary
Table 63. Proreo Pharma AG Pulmonary Hypertension Drug Product Offerings
Table 64. Proreo Pharma AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. Proreo Pharma AG Key News & Latest Developments
Table 66. Vicore Pharma AB Company Summary
Table 67. Vicore Pharma AB Pulmonary Hypertension Drug Product Offerings
Table 68. Vicore Pharma AB Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 69. Vicore Pharma AB Key News & Latest Developments
Table 70. Biolab Sanus Farmaceutica Ltda. Company Summary
Table 71. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Product Offerings
Table 72. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 73. Biolab Sanus Farmaceutica Ltda. Key News & Latest Developments
Table 74. Hanmi Pharmaceuticals, Co. Ltd. Company Summary
Table 75. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Product Offerings
Table 76. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 77. Hanmi Pharmaceuticals, Co. Ltd. Key News & Latest Developments
Table 78. Pulmonary Hypertension Drug Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 79. Global Pulmonary Hypertension Drug Capacity Market Share of Key Manufacturers, 2021-2023
Table 80. Global Pulmonary Hypertension Drug Production by Region, 2018-2023 (K Pcs)
Table 81. Global Pulmonary Hypertension Drug Production by Region, 2024-2029 (K Pcs)
Table 82. Pulmonary Hypertension Drug Market Opportunities & Trends in Global Market
Table 83. Pulmonary Hypertension Drug Market Drivers in Global Market
Table 84. Pulmonary Hypertension Drug Market Restraints in Global Market
Table 85. Pulmonary Hypertension Drug Raw Materials
Table 86. Pulmonary Hypertension Drug Raw Materials Suppliers in Global Market
Table 87. Typical Pulmonary Hypertension Drug Downstream
Table 88. Pulmonary Hypertension Drug Downstream Clients in Global Market
Table 89. Pulmonary Hypertension Drug Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Pulmonary Hypertension Drug Segment by Type in 2022
Figure 2. Pulmonary Hypertension Drug Segment by Application in 2022
Figure 3. Global Pulmonary Hypertension Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Pulmonary Hypertension Drug Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Pulmonary Hypertension Drug Revenue, 2018-2029 (US$, Mn)
Figure 7. Pulmonary Hypertension Drug Sales in Global Market: 2018-2029 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Pulmonary Hypertension Drug Revenue in 2022
Figure 9. By Type - Global Pulmonary Hypertension Drug Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Pulmonary Hypertension Drug Revenue Market Share, 2018-2029
Figure 11. By Type - Global Pulmonary Hypertension Drug Sales Market Share, 2018-2029
Figure 12. By Type - Global Pulmonary Hypertension Drug Price (USD/Pcs), 2018-2029
Figure 13. By Application - Global Pulmonary Hypertension Drug Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Pulmonary Hypertension Drug Revenue Market Share, 2018-2029
Figure 15. By Application - Global Pulmonary Hypertension Drug Sales Market Share, 2018-2029
Figure 16. By Application - Global Pulmonary Hypertension Drug Price (USD/Pcs), 2018-2029
Figure 17. By Region - Global Pulmonary Hypertension Drug Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Pulmonary Hypertension Drug Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Pulmonary Hypertension Drug Revenue Market Share, 2018-2029
Figure 20. By Region - Global Pulmonary Hypertension Drug Sales Market Share, 2018-2029
Figure 21. By Country - North America Pulmonary Hypertension Drug Revenue Market Share, 2018-2029
Figure 22. By Country - North America Pulmonary Hypertension Drug Sales Market Share, 2018-2029
Figure 23. US Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Pulmonary Hypertension Drug Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Pulmonary Hypertension Drug Sales Market Share, 2018-2029
Figure 28. Germany Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 29. France Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Pulmonary Hypertension Drug Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Pulmonary Hypertension Drug Sales Market Share, 2018-2029
Figure 37. China Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 41. India Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Pulmonary Hypertension Drug Revenue Market Share, 2018-2029
Figure 43. By Country - South America Pulmonary Hypertension Drug Sales Market Share, 2018-2029
Figure 44. Brazil Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Pulmonary Hypertension Drug Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Pulmonary Hypertension Drug Sales Market Share, 2018-2029
Figure 48. Turkey Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Pulmonary Hypertension Drug Revenue, (US$, Mn), 2018-2029
Figure 52. Global Pulmonary Hypertension Drug Production Capacity (K Pcs), 2018-2029
Figure 53. The Percentage of Production Pulmonary Hypertension Drug by Region, 2022 VS 2029
Figure 54. Pulmonary Hypertension Drug Industry Value Chain
Figure 55. Marketing Channels

★調査レポート[世界の肺高血圧症治療薬市場予測2023-2029：IK-3001、クエン酸シルデナフィルIMD、IK-7002、リオシグアト、SAR-407899、その他] (コード：MMG23LY8620)販売に関する免責事項を必ずご確認ください。

★調査レポート[世界の肺高血圧症治療薬市場予測2023-2029：IK-3001、クエン酸シルデナフィルIMD、IK-7002、リオシグアト、SAR-407899、その他]についてメールでお問い合わせ

MarketReport.jp

世界の肺高血圧症治療薬市場予測2023-2029：IK-3001、クエン酸シルデナフィルIMD、IK-7002、リオシグアト、SAR-407899、その他

市場調査レポート・産業資料総合販売サイト www.MarketReport.jp

市場調査レポート・産業資料 総合販売サイト www.MarketReport.jp

市場調査レポート・産業資料総合販売サイト www.MarketReport.jp